Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zx-7101
- Development stage
- Unknown
- Lead developer
- Zenshine Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZX-7101 is the active metabolite of ZX-7101A, a novel small molecule antiviral developed as a **cap-dependent endonuclease inhibitor** for the treatment of influenza A and B infections. ZX-7101A is an oral prodrug rapidly converted in vivo to ZX-7101, which inhibits the polymerase acidic (PA) protein of the influenza virus, blocking viral mRNA synthesis. Clinical data show that single oral doses of 40 or 80 mg are effective and well tolerated in uncomplicated influenza, and development includes both tablet and oral suspension formulations for adult and pediatric populations[1][2][3][4][5].
- Other names
- 玛赛洛沙韦
02
Targets
CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)p3 (Amyloid-beta p3 fragment)
Beyond the preview
Go deeper on zx-7101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zx-7101.